|
|
|
||||||||||
Clinical SpecialistGeneral Pediatrics, Department of Pharmacy, Children's Hospital of The King's Daughters; Assistant Professor, Pediatrics, Eastern Virginia Medical School, Norfolk, VA
Pediatric Gastroenterologist, Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of The King's Daughters
at time of writing, Pharmacy Student, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
Director of Pharmacy, Department of Pharmacy, Children's Hospital of The King's Daughters
Reprints: Dr. Chicella, Department of Pharmacy, Children's Hospital of The King's Daughters, 601 Children's Ln., Norfolk, VA 23507-1910, fax 757/668-7482, Chicelmf{at}chkd.org
OBJECTIVE: To review the pharmacology, safety, and efficacy of the prokinetic agents metoclopramide and erythromycin in children.
DATA SOURCES: English-language literature was accessed using MEDLINE (1970June 2004) with metoclopramide, erythromycin, macrolides, gastroesophageal reflux, and gastrointestinal motility as the search terms.
STUDY SELECTION AND DATA EXTRACTION: Abstracts and original research articles were included. Preference was given to published controlled trials. Articles providing descriptions of pharmacology, safety, and effectiveness of metoclopramide and erythromycin for the treatment of gastroesophageal reflux (GER) were also used in this review.
DATA SYNTHESIS: Some authors advocate using a prokinetic agent along with acid suppression for treatment of GER in children. The 2 prokinetic agents most commonly used are erythromycin and metoclopramide. Erythromycin has numerous observational reports and controlled trials demonstrating its efficacy in improving feeding tolerance in children. Adverse drug reactions associated with its use were uncommon in prospective controlled trials. Few data support the use of metoclopramide for management of GER, and the potential adverse effects associated with its use need to be considered before prescribing.
CONCLUSIONS: The literature supports the use of erythromycin as a prokinetic agent. Many children with GER are adequately controlled with acid suppression alone; however, if use of a prokinetic agent is warranted, erythromycin in combination with acid suppression should be considered. Given the lack of prospective controlled studies demonstrating metoclopramide's efficacy and safety in the treatment of GER in children, metoclopramide should not be considered a treatment option.
Key Words: erythromycin, gastroesophageal reflux, gastrointestinal motility, metoclopramide, pediatrics
Published Online, March 8, 2005. www.theannals.com, DOI 10.1345/aph.1E411
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-014-H01
This article has been cited by other articles:
![]() |
S. Keady Update on drugs for gastro-oesophageal reflux disease Arch. Dis. Child. Ed. Pract., August 1, 2007; 92(4): ep114 - ep118. [Full Text] [PDF] |
||||
![]() |
C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Boesch, C. Daines, J. P. Willging, A. Kaul, A. P. Cohen, R. E. Wood, and R. S. Amin Advances in the diagnosis and management of chronic pulmonary aspiration in children Eur. Respir. J., October 1, 2006; 28(4): 847 - 861. [Abstract] [Full Text] [PDF] |
||||